• About
    • Company Overview
    • Management Team
    • Board of Directors
    • Science Advisors
    • Neurology Advisors
    • Ophthalmology Advisors
    • Contacts
  • Science
    • Publications
    • Collaborators
  • Pipeline
    • Infantile Neuroaxonal Dystrophy (INAD)
    • Friedreich’s Ataxia (FA)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Progressive Supranuclear Palsy (PSP)
    • Dry AMD
    • Future Targets
  • Patient Resources
    • Expanded Access Policy
    • Clinical Trials
    • Additional Resources
  • News & Events
    • Press Releases
    • News
    • Events
    • Videos
  • Careers
HomeManagementPeter D. Milner, MD

Peter D. Milner, MD

Chief Medical Officer

Peter D. Milner

Peter D. Milner, M.D., currently serves as chairman of Armetheon, a California company conducting a Phase 3 trial of its novel oral anticoagulant. He was previously chief executive officer of Heart Metabolics, where he raised capital for and organized the late-stage development of an orphan treatment for a hypertrophic cardiomyopathy (HCM), rare genetic heart disease. In 2007, Dr. Milner co-founded Optivia Biotechnology, a leading transporter biology company.

Additionally, Dr. Milner is credited with co-founding ARYx Therapeutics (NASDAQ:ARYX) and CV Therapeutics (NASDAQ:CVTX).  At ARYx Therapeutics he served as CEO and president, during which time he co-invented and developed four novel drug candidates.  While a member of the CV Therapeutics senior management team, Dr. Milner participated in the in-licensing and invention of several successful pharmaceutical products. His contributions to the success of CV Therapeutics led to the company’s acquisition by Gilead for $1.5B in 2009.

Prior to joining industry, Dr. Milner was as an assistant professor of medicine at Washington University in St. Louis, where his research led to the discovery of pleiotrophin (PTN), a novel growth factor that regulates the epithelial mesenchymal transition (EMT). He received his medical degree from University of Liverpool in 1980 and undertook post-graduate training at Johns Hopkins Hospital and The University of Virginia.

Dr. Milner is a board certified cardiologist, a Fellow of the American College of Cardiology (FACC), co-inventor on 50 patents and author of 29 original scientific articles that have appeared in Science, Biochemistry, Circulation, Cancer, JCI, and JBC. He serves as adjunct clinical faculty at Stanford University and as a board member of the California Healthcare Institute (CHI), where he has been responsible for championing various pieces of legislation in particular, the 2011 Leahy-Smith Patent Reform Act and the 2012 GAIN (Generate Antibiotic Incentives Now) Act.

About
Science
  • Publications
Pipeline
  • Clinical
  • Preclinical
  • Future Targets
Patient Resources
  • Expanded Access Policy
News & Events
Careers
RETROTOPE, 4300 EL CAMINO REAL, SUITE 201, LOS ALTOS, CA 94022
Copyright ©️ 2015-2021 Retrotope Inc.
You are leaving Retrotope’s website. Retrotope does not guarantee the accuracy or completeness of the information contained on any third-party sites, nor does it endorse any of the opinions or information contained on those sites. Please click CONFIRM to continue. CONFIRM